DALLAS, Dec. 14, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced a letter to shareholders to further confirm recent announcements from the company and to outline measures underway to update its public disclosures. On November 15th, the company announced the acquisition of NCM Biotech in a transaction that changed the business direction of the company. Prior to that acquisition, the company’s previous business focus on marina management had languished. In addition to the marina management business not advancing as originally planned, the company had fallen behind in the timely filing of the disclosures required by OTCMarkets. Accordingly, OTCMarkets had posted a “stop-sign” icon on the KALY OTCMarkets page to warn investors that the company was not current in its required filings and to take appropriate precautions in investment decisions associated with KALY. Yesterday, December 13, 2018, OTCMarkets updated its precautionary notice regarding KALY to a Caveat Emptor icon to further raise investor precaution in regard to investment decisions associated with KALY. The letter today is intended to confirm the recent announcements made in conjunction with the November 15th acquisition and the company’s corresponding new business direction, in addition to addressing efforts underway to bring all KALY’s required disclosures current with OTCMarkets standards. The letter is included in its entirety below.
KALY Confirms Acquisition, Assets, Contracts, Products and Partnerships
Dec 14, 2018
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers